VivoSim Labs Net Cash Flow 2011-2025 | VIVS

VivoSim Labs net cash flow from 2011 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

VivoSim Labs Net Cash Flow 2011-2025 | VIVS

VivoSim Labs net cash flow from 2011 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.3B
Amgen (AMGN)$153.1B
Gilead Sciences (GILD)$137.2B
Vertex Pharmaceuticals (VRTX)$99B
Bristol Myers Squibb (BMY)$91.2B
CSL (CSLLY)$84.8B
GSK (GSK)$75B
Regeneron Pharmaceuticals (REGN)$59.9B
Alnylam Pharmaceuticals (ALNY)$56.1B
Argenex SE (ARGX)$41.2B
BioNTech SE (BNTX)$26.8B
Insmed (INSM)$21.1B
Royalty Pharma (RPRX)$20.9B
Biogen (BIIB)$19B
Incyte (INCY)$15.2B
Illumina (ILMN)$14.5B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.8B
BioMarin Pharmaceutical (BMRN)$11.6B
Ascendis Pharma (ASND)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
QIAGEN (QGEN)$10.6B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.8B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Bio-Techne Corp (TECH)$7.8B
Halozyme Therapeutics (HALO)$7.7B